BR112015028429A2 - Composição imunogênica baseada em um imunógeno do peptídeo gastrina-17, uma vacina compreendendo a composição imunogênica, um kit para preparação da composição imunogênica, e sua utilização médica no tratamento de doenças gastrina dependentes - Google Patents
Composição imunogênica baseada em um imunógeno do peptídeo gastrina-17, uma vacina compreendendo a composição imunogênica, um kit para preparação da composição imunogênica, e sua utilização médica no tratamento de doenças gastrina dependentesInfo
- Publication number
- BR112015028429A2 BR112015028429A2 BR112015028429A BR112015028429A BR112015028429A2 BR 112015028429 A2 BR112015028429 A2 BR 112015028429A2 BR 112015028429 A BR112015028429 A BR 112015028429A BR 112015028429 A BR112015028429 A BR 112015028429A BR 112015028429 A2 BR112015028429 A2 BR 112015028429A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic composition
- gastrin
- vaccine
- kit
- treatment
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 13
- 108010066264 gastrin 17 Proteins 0.000 title abstract 4
- 230000001419 dependent effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000002496 gastric effect Effects 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102400000921 Gastrin Human genes 0.000 abstract 2
- 108010052343 Gastrins Proteins 0.000 abstract 1
- 241000282560 Macaca mulatta Species 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 abstract 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSIÇÃO IMUNOGÊNICA BASEADA EM UM IMUNÓGENO DO PEPTÍDEO GASTRINA-17, UMA VACINA COMPREENDENDO A COMPOSIÇÃO IMUNOGÊNICA, UM KIT PARA PREPARAÇÃO DA COMPOSIÇÃO IMUNOGÊNICA, E SUA UTILIZAÇÃO MÉDICA NO TRATAMENTO DE DOENÇAS GASTRINA DEPENDENTES. A presente invenção refere-se a uma composição imunogênica compreendendo a. um adjuvante direcionado compreendendo pelo menos uma parte anti-CD32 ligada a um ligante de TLR9 e uma primeira alfa-hélice peptídica; e b. um imunógeno de peptídeo gastrina-17 ligado a uma segunda alfahélice peptídica enrolada à primeira alfa-hélice, cujo imunógeno de peptídeo é qualquer um de (i) gastrina-17 humana compreendendo a sequência de aminoácidos da SEQ ID 1, ou um fragmento desta compreendendo a sequência de aminoácidos da SEQ ID 2, ou pelo menos 4 aminoácidos N-terminais da SEQ ID 2; (ii) um análogo de (i), de preferência de origem do macaco rhesus ou murino; e/ou (iii) uma variante funcionalmente ativa de qualquer um de (i) ou (ii), com um, dois, três ou quatro mutações pontuais na sequência de aminoácidos da SEQ ID 2. A invenção fornece ainda um kit para produzir tal composição imunogênica, uma vacina compreendendo a referida composição imunogênica e sua utilização médica, tal como para o tratamento de doenças gastrina dependentes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168565 | 2013-05-21 | ||
| PCT/EP2014/060088 WO2014187743A1 (en) | 2013-05-21 | 2014-05-16 | Gastrin peptide immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015028429A2 true BR112015028429A2 (pt) | 2017-09-19 |
Family
ID=48446168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015028429A BR112015028429A2 (pt) | 2013-05-21 | 2014-05-16 | Composição imunogênica baseada em um imunógeno do peptídeo gastrina-17, uma vacina compreendendo a composição imunogênica, um kit para preparação da composição imunogênica, e sua utilização médica no tratamento de doenças gastrina dependentes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10328134B2 (pt) |
| EP (1) | EP2999485B1 (pt) |
| JP (1) | JP6395816B2 (pt) |
| CN (1) | CN105407919B (pt) |
| AU (1) | AU2014270595B2 (pt) |
| BR (1) | BR112015028429A2 (pt) |
| CA (1) | CA2912736C (pt) |
| ES (1) | ES2665780T3 (pt) |
| HU (1) | HUE037252T2 (pt) |
| PL (1) | PL2999485T3 (pt) |
| PT (1) | PT2999485T (pt) |
| RU (1) | RU2664197C2 (pt) |
| WO (1) | WO2014187743A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016184862A1 (en) | 2015-05-18 | 2016-11-24 | Oncoqr Ml Gmbh | Her2/neu immunogenic composition |
| JP6799327B2 (ja) * | 2015-06-19 | 2020-12-16 | 国立大学法人静岡大学 | 免疫機能発達促進剤及び成長促進剤 |
| US11090381B2 (en) | 2015-09-01 | 2021-08-17 | Oncoqr Ml Gmbh | Coiled-coil connector |
| WO2018232230A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| CN111150842B (zh) * | 2019-12-31 | 2023-09-05 | 优锐生物医药科技(深圳)有限公司 | 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用 |
| WO2022155320A1 (en) * | 2021-01-13 | 2022-07-21 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2063912T3 (es) * | 1989-01-24 | 1995-01-16 | Aphton Corp | Composiciones inmunogenicas frente a peptidos de gastrina. |
| US5023077A (en) * | 1989-01-24 | 1991-06-11 | Aphton Corporation | Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease |
| US5468494A (en) | 1993-11-12 | 1995-11-21 | Aphton Corp. | Immunogenic compositions against human gastrin 17 |
| GB9516760D0 (en) | 1995-08-16 | 1995-10-18 | Sandoz Ltd | Organic compounds |
| WO1997028821A1 (en) * | 1996-02-08 | 1997-08-14 | Aphton Corp. | Immunological methods for the treatment of gastrointestinal cancer |
| JP5576592B2 (ja) | 2004-03-29 | 2014-08-20 | キャンサー アドヴァンシズ インコーポレイテッド | ガストリンホルモンに対するモノクローナル抗体 |
| US7574259B1 (en) * | 2004-11-12 | 2009-08-11 | Pacesetter, Inc. | Capture threshold and lead condition analysis |
| EP1829895A1 (en) * | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| EP2046334B1 (en) | 2006-07-25 | 2014-05-21 | Vecta Ltd. | Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi |
| EP2397547A4 (en) * | 2009-02-10 | 2012-09-05 | Univ Ryukyus | ACTIVE TRANSPORT, AS WELL AS AUXILIARY AND VACCINATE THEREOF |
| US10434170B2 (en) | 2012-07-13 | 2019-10-08 | S-Target Therapeutics Gmbh | Immunoregulatory vaccine |
| EP3297547B1 (en) | 2015-05-21 | 2023-11-01 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Device for injection, photoactivation and solidifaction of liquid embolic material in the vascular system or other organic cavities |
-
2014
- 2014-05-16 BR BR112015028429A patent/BR112015028429A2/pt not_active Application Discontinuation
- 2014-05-16 PT PT147241020T patent/PT2999485T/pt unknown
- 2014-05-16 CA CA2912736A patent/CA2912736C/en active Active
- 2014-05-16 RU RU2015154795A patent/RU2664197C2/ru active
- 2014-05-16 CN CN201480032978.4A patent/CN105407919B/zh active Active
- 2014-05-16 JP JP2016514341A patent/JP6395816B2/ja active Active
- 2014-05-16 PL PL14724102T patent/PL2999485T3/pl unknown
- 2014-05-16 ES ES14724102.0T patent/ES2665780T3/es active Active
- 2014-05-16 AU AU2014270595A patent/AU2014270595B2/en active Active
- 2014-05-16 WO PCT/EP2014/060088 patent/WO2014187743A1/en active Application Filing
- 2014-05-16 US US14/892,973 patent/US10328134B2/en active Active
- 2014-05-16 EP EP14724102.0A patent/EP2999485B1/en active Active
- 2014-05-16 HU HUE14724102A patent/HUE037252T2/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2664197C2 (ru) | 2018-08-15 |
| WO2014187743A1 (en) | 2014-11-27 |
| US20160129096A1 (en) | 2016-05-12 |
| PL2999485T3 (pl) | 2018-07-31 |
| ES2665780T3 (es) | 2018-04-27 |
| PT2999485T (pt) | 2018-04-30 |
| CN105407919B (zh) | 2019-08-06 |
| RU2015154795A (ru) | 2017-06-26 |
| US10328134B2 (en) | 2019-06-25 |
| CA2912736C (en) | 2021-09-07 |
| CA2912736A1 (en) | 2014-11-27 |
| JP2016523837A (ja) | 2016-08-12 |
| JP6395816B2 (ja) | 2018-09-26 |
| AU2014270595A1 (en) | 2015-11-12 |
| EP2999485B1 (en) | 2018-01-31 |
| AU2014270595B2 (en) | 2019-04-04 |
| CN105407919A (zh) | 2016-03-16 |
| HUE037252T2 (hu) | 2018-08-28 |
| EP2999485A1 (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028429A2 (pt) | Composição imunogênica baseada em um imunógeno do peptídeo gastrina-17, uma vacina compreendendo a composição imunogênica, um kit para preparação da composição imunogênica, e sua utilização médica no tratamento de doenças gastrina dependentes | |
| BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| MX2019010460A (es) | Plataforma de identificacion de peptidos inmunogenicos basada en poblacion. | |
| EP3363458A3 (en) | A peptide | |
| BR112015023105A8 (pt) | construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo. | |
| BR112012022676A2 (pt) | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit | |
| BR112012021329A2 (pt) | anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo. | |
| BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112016003358A2 (pt) | método para aumentar a expressão de proteínas codificadas por rna | |
| IN2014KN01715A (pt) | ||
| BRPI0607326B8 (pt) | composição de vacina, uso da referida composição e kit em partes | |
| BR112016012538A2 (pt) | peptídeos citotóxicos e conjugados dos mesmos | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| NZ628449A (en) | Neisseria meningitidis compositions and methods thereof | |
| JP2013542919A5 (pt) | ||
| BR112013016870A2 (pt) | formulação, método para obter uma formulação de peptídeo, e, uso de uma formulação | |
| AR103896A1 (es) | Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3 | |
| NZ766003A (en) | Factor h binding protein variants and methods of use thereof | |
| CO2017012675A2 (es) | Péptidos lipidados resistentes a proteasas | |
| BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
| CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares | |
| BR112021023957A2 (pt) | Peptídeos | |
| EA201890163A1 (ru) | Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью | |
| BR112021020777A2 (pt) | Vacina de subunidade do csfv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |